



Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions

Hilary Smith Connery, MD, PhD

Learning Objective: After participating in this activity, learners should be better able to:

Evaluate the rationale for and current evidence supporting medication-assisted treatment of opioid use disorder.

Abstract: Medication-assisted treatment of opioid use disorder with physiological dependence at least doubles rates of opioid-abstinence outcomes in randomized, controlled trials comparing psychosocial treatment of opioid use disorder with medication versus with placebo or no medication. This article reviews the current evidence for medication-assisted treatment of opioid use disorder and also presents clinical practice imperatives for preventing opioid overdose and the transmission of infectious disease. The evidence strongly supports the use of agonist therapies to reduce opioid use and to retain patients in treatment, with methadone maintenance remaining the gold standard of care. Combined buprenorphine/naloxone, however, also demonstrates significant efficacy and favorable safety and tolerability in multiple populations, including youth and prescription opioid-dependent individuals, as does buprenorphine monotherapy in pregnant women. The evidence for antagonist therapies is weak. Oral naltrexone demonstrates poor adherence and increased mortality rates, although the early evidence looks more favorable for extended-release naltrexone, which has the advantages that it is not subject to misuse or diversion and that it does not present a risk of overdose on its own. Two perspectives—individualized treatment and population management—are presented for selecting among the three available Food and Drug Administration–approved maintenance therapies for opioid use disorder. The currently unmet challenges in treating opioid use disorder are discussed, as are the directions for future research.

Keywords: buprenorphine, medication-assisted treatment, methadone, naltrexone, opioid use disorder

Opioid use disorder (OUD) is defined by the *Diagnostic and Statistical Manual of Mental Disorders* (fifth edition)¹ as the maladaptive use of opioids, prescribed or illicit, resulting in two or more criteria that reflect impaired health or function over a 12-month period. OUD is scaled according to severity (mild/moderate/severe) and does not require physiological tolerance or dependence in order to be considered a substance use disorder. Text Box 1 summarizes core criteria and provides a mnemonic to assist clinical diagnosis and teaching.

From Harvard Medical School and Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA.

Original manuscript received 21 June 2014, accepted for publication subject to revision 14 September 2014; revised manuscript received 3 November 2014.

Correspondence: Hilary Smith Connery, MD, PhD, Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill St., Belmont, MA 02478. Email: hconnery@mclean.harvard.edu

CME *Harvard Review of Psychiatry* offers CME for readers who complete questions about featured articles. Questions can be accessed from the *Harvard Review of Psychiatry* website (www.harvardreviewofpsychiatry.org) by clicking the CME tab. Please read the featured article and then log into the website for this educational offering. If you are already online, [click here](#) to go directly to the CME page for further information.

© 2015 President and Fellows of Harvard College

DOI: 10.1097/HRP.0000000000000075

In the United States, rates of prescription opioid analgesic misuse rose exponentially in the preceding decade,² as has the treatment received for both heroin use disorder and opioid analgesic use disorder.³ Among persons aged 12 years and older, self-reported lifetime misuse of heroin and opioid analgesics is estimated at nearly 2% and 14% of the population, respectively.³

Effective treatment of OUD has been identified as a national priority to reduce the rates and societal costs of individual disability associated with OUD, the infectious disease burden associated with intravenous opioid use (especially hepatitis C [HCV] and HIV transmission), and escalating rates of accidental opioid overdose deaths and pediatric opioid ingestions.^{2,4–8} Prior reviews of medication-assisted treatment (MAT) of OUD provide useful guidance to clinicians,^{9–12} yet algorithms for selecting medication treatment require continuous updating to remain current with the emerging evidence. The goal of this review is to succinctly provide this clinical update and to highlight unresolved challenges in treating OUD.

METHODS

All randomized, controlled trials (RCTs) with English abstracts on medical management of OUD were searched using

Text Box 1**DSM-5 Criteria for Opioid Use Disorder OUD Presented in the Author's Mnemonic**

Long Time Craving Control ⇒ TRASHeD ⇒ Withdrawn
 Longer use or larger amounts used than intended
 Time spent obtaining opioids, using, or recovering from use
 Craving opioids
 Failed attempts to **control** or cut back opioid use
 Opioid **tolerance**
 Role failure due to opioid use
 Activities reduced because of recurrent opioid use
 Social problems resulting from recurrent opioid use
 Health problems resulting from recurrent opioid use
 Dangerous opioid use: use despite risk of physical hazard
 Opioid **withdrawal** syndrome

In the above mnemonic, the satisfaction of two or more criteria in a 12-month period defines opioid use disorder. Criteria are listed in order of severity, progressing from milder criteria to those criteria that most impair function or cause distress. Severity scaling is determined by the number of criteria that are met and may be remembered by “5 or 4 is a moderate score” (2–3 = mild; ≥6 = severe).

PubMed mesh terms [opioid dependence OR opioid addiction] AND medication, yielding 502 abstracts. These articles were screened for inclusion as contributing to the evidence on MAT for OUD. The resulting set of references was supplemented, based on an examination of abstracts, to include relevant case reports, reviews, meta-analyses, and clinical trials. Finally, the Provider's Clinical Support System for Medication-Assisted Treatment website (www.pcsmat.org), which contains current practice training and educational support for opioid MAT, was reviewed to identify elements of expert consensus beyond the current evidence.

RESULTS: OVERVIEW OF MAT FOR OUD**Mu-Opioid Receptor Targeted Stabilization of OUD**

The Food and Drug Administration (FDA) has approved three medications for preventing opioid relapse and for stabilization/maintenance treatment of OUD: buprenorphine, naltrexone, and methadone. All three are ligands that bind to central mu-opioid receptors as the molecular target for their therapeutic activity, yet they differ significantly in their respective intrinsic activities at the mu-opioid receptor, their pharmacokinetic and pharmacodynamic properties (with effects on efficacy and toxicity), and the mechanisms by which they confer relapse-prevention protection to treated individuals (Table 1).

In selecting MAT, the first consideration is whether an individual has OUD with physiological dependence. All three

medications are FDA approved based on RCTs demonstrating efficacy and safety in OUD with historical symptoms of physiological dependence (Table 2). The addition of agonist maintenance to relapse-prevention treatment at least doubles the probability, compared to relapse-prevention treatment alone, that an individual will achieve opioid abstinence during active treatment,^{24–27} and the addition of antagonist maintenance nearly doubles opioid abstinence.²³ Oral naltrexone, although FDA approved to treat OUD, is excluded from consideration here due to poor adherence rates and significant opioid-overdose mortality following medication discontinuation in clinical studies of OUD treatment outcomes.^{28–31} Attempts to pair oral naltrexone with psychosocial interventions aimed at improving compliance and retention in treatment have not yet demonstrated sustained positive results.^{29,32} Naltrexone implant and buprenorphine implant are not yet FDA approved for OUD, and trials to date provide insufficient evidence of safety and efficacy.^{33,34}

The evidence for efficacy both in reducing opioid use and retaining patients in care is strongest for agonist treatment; methadone maintenance remains the gold standard of care for OUD.³⁵ The evidence for antagonist treatment of OUD remains comparatively weak, given the mortality risk and poor adherence with oral naltrexone, plus the limited RCT evidence for extended-release naltrexone (naltrexone ER). The latter includes only a trial²³ with open-label extension¹⁹ in a Russian population without access to agonist therapy and a small trial of employment contingency to improve naltrexone ER adherence in a US cohort.³⁶ Also in Russia, a small RCT of employment contingency to improve adherence used a different, non-FDA-approved formulation of naltrexone ER. Efficacy in reducing opioid use (60%–70% opioid-free urines) was similar to the two above trials cited, and the employment-contingency condition improved adherence but did not affect opioid use.³⁷ These studies do not adequately address either safety following medication discontinuation or efficacy compared to agonist therapy, and they pose problems for generalizability. A phase 4, multisite RCT comparing naltrexone ER to buprenorphine/naloxone maintenance is currently under way, with the expectation that results will resolve safety and efficacy questions regarding naltrexone ER as a treatment for OUD (NIDA Clinical Trials Network protocol 0051 [Principal Investigator: John Rotrosen/New York University School of Medicine]; ClinicalTrials.gov identifier NCT02032433).

Unknown Aspects of Mu-Opioid Receptor Functional Activity in MAT

Although it is commonly accepted that the functional effects of MAT differ according to their respective intrinsic activities at central mu-opioid receptors, this view is oversimplified. The many complexities of mu-opioid receptor ligand binding and biased agonism (e.g., “functional selectivity” according to mu-opioid receptor/effector coupling and intracellular environment, and agonist-induced receptor conformational changes with prolonged agonist exposure)^{38–40} are only now being

Table 1			
Comparison of FDA-Approved Medications to Treat Opioid Use Disorder with Physiological Opioid Dependence			
Medication	MOR intrinsic activity MOR binding	Differential pharmacology affecting MOR activation at therapeutic dose	Mechanism of relapse prevention
Buprenorphine	Partial agonist High affinity $K_i^* = 0.2 \text{ nM}$	Slow MOR dissociation allows thrice-weekly sublingual dosing and possibility of high-dose weekly formulations ^{13–15} Highest known MOR affinity makes rescue from overdose by naloxone less effective; ¹⁶ rapid precipitation of withdrawal if full agonists present	Reduces opioid craving, withdrawal, and stress reactivity Competitively blocks or reduces the reinforcing effects of other opioids
Methadone	Full agonist High affinity $K_i^* = 3.4 \text{ nM}$	Long terminal half-life (up to 120 hours) with delayed steady-state efficacy poses increased MOR toxicity risk during induction phase ¹⁷ Multiple drug-drug interactions pose both opioid-toxicity and withdrawal risks during treatment ¹⁸	Reduces opioid craving, withdrawal, and stress reactivity Reduces the reinforcing effects of other opioids
Naltrexone ER	Antagonist High affinity $K_i^\dagger = 0.26\text{--}0.34 \text{ nM}$	Lack of MOR agonism associated with delayed stabilization of opioid craving ¹⁹ Safety concern based on rodent data demonstrating chronic naltrexone exposure increases respiratory-depression risk upon opioid agonist reexposure ²⁰	Competitively blocks reinforcing effects of opioid agonists Reductions in craving are psychologically mediated (reduced anticipatory expectancies)

* Equilibrium dissociation constant for the test compound and relative values are from Volpe et al. (2011).²¹
† Equilibrium dissociation constant is from Yuan et al. (2013).²²
MOR, mu-opioid receptor; ER, extended release; nM, nanomoles.

discovered, and may account for the clinical effects of these medications that remain poorly understood and that appear to vary widely among individuals. For example, little is known about why only certain individuals develop OUD following recurrent opioid exposure, although population studies in patients receiving opioid analgesics identify co-occurring substance use and mental illness as risk factors for

developing OUD,⁴¹ and a recent meta-analysis suggests that the rs1799971 polymorphism of the *OPRM1* gene may confer vulnerability to OUD following exposure to either heroin or prescription opioids.⁴² Clinically, dosing needs in agonist maintenance therapies differ significantly among individuals, and most patients do not develop tolerance to the relapse-prevention efficacy of buprenorphine or methadone

Table 2			
Opioid-Abstinence Rates with Medication Compared to Nonmedication^a			
Medication ^b	Percentage opioid free on medication	Percentage opioid free on placebo/detoxification	Study
Naltrexone ER	36	23	Krupitsky et al. (2011) ²³
Buprenorphine/naloxone	20–50	6	Fudala et al. (2003) ²⁴ Weiss et al. (2011) ^{25,c}
Buprenorphine/naloxone	60	20	Woody et al. (2008) ^{26,d}
Methadone	60	30	Mattick et al. (2009) ²⁷

ER, extended release.
^a The randomized, controlled clinical trials summarized here paired medication maintenance with evidence-based psychosocial treatments and opioid use self-report data that were confirmed with urine toxicology. Clinical settings for treatment delivery may affect the rates of opioid use in the nonmedication control groups. The trials predominantly used adult opioid use disorder populations, with the majority being heroin dependent or having mixed dependence on heroin and prescription opioids.
^b All medications are FDA approved.
^c Population was prescription opioid-dependent patients.
^d Population was youth aged 14–21 years.

maintenance. These observations suggest dynamic factors beyond ligand intrinsic activity at mu-opioid receptors. Whistler⁴³ has presented a helpful summary of the converging evidence that opioid agonists having both high efficacy and high propensity to produce mu-opioid receptor desensitization and endocytosis (“molecular trafficking”) have lower liability for abuse and produce less tolerance than opioid agonists that induce comparatively little endocytosis. Examples of the former include endogenous opioid ligands and methadone, whereas the latter include morphine, codeine, buprenorphine,⁴⁴ and most commonly misused prescription opioids. Thus, endocytosis may help to explain the lack of tolerance observed for relapse-prevention efficacy with methadone maintenance but would not explain the same observation with buprenorphine maintenance.

Within methadone-maintained patients, pharmacogenomic studies identify variability in treatment response and pharmacokinetics associated with the variants of several genes (*OPRM1*, *ARRB2*, *KCNJ6*, *ABCB1*) and hepatic CYP450 enzymes, suggesting layers of complexity in any given individual’s treatment response.⁴⁵ For example, a recently published meta-analysis demonstrates that individuals homozygous for the CYP2B6*6 polymorphism are slow metabolizers of both the R- and S-enantiomers of methadone and therefore would be expected to have lower dosing requirements.⁴⁶ The utility of pharmacogenomic screening may be especially important in future clinical practice with methadone maintenance.

Comparing MAT Tolerability and Convenience

RCTs examining methadone, buprenorphine, and extended-release naltrexone injection stabilization are all associated with acceptable adverse-effect profiles and with an acceptable level of patient tolerance.^{23–27} Agonist treatment is associated most frequently with opioid-class effects such as dose-dependent sedation, constipation, sweating, neurocognitive impairment, and sexual dysfunction. Dose-dependent respiratory depression is an adverse effect mainly of methadone, a full mu-opioid agonist, whereas the partial-agonist properties of buprenorphine prevent dose-dependent respiratory depression greater than 50% reduction of baseline even at IV doses of 2 mcg/kg in opioid-naive healthy volunteers.⁴⁷ This “ceiling effect” on respiratory depression has obvious benefits for tolerability as well as for accidental or intentional overdose. Similarly, buprenorphine’s partial-agonist properties have a protective “ceiling effect” that does not induce euphoria in opioid-tolerant individuals, whereas methadone-induced euphoria may be present in the early treatment of OUD but decreases with steady-state dosing stabilization.⁴⁸

Naltrexone ER is associated most commonly with insomnia, site reactions to injection, clinically insignificant elevation of transaminases, hypertension, nasopharyngitis, and influenza.^{19,23}

Patient convenience for dosing is least burdensome with monthly injections of naltrexone ER or monthly maintenance visits with office-based buprenorphine/naloxone—both modeling typical outpatient treatment for severe chronic

illness. Dosing is most burdensome with required observed daily dosing in opioid treatment programs prescribing methadone or buprenorphine maintenance in the early phases of recovery.

Retention in Treatment After the Initiation of MAT

All three medications show improved retention in treatment compared to placebo or no medication.^{24–27} Head-to-head comparisons are mainly available for buprenorphine versus methadone maintenance, with methadone demonstrating the highest rates of treatment retention in all studies,^{35,49} including the treatment of pregnant women⁵⁰ and those with HIV.⁵¹ One RCT conducted in Iran compared all three medications in a cohort of men dependent on intravenous buprenorphine and found that retention in treatment over a 24-week period was best with methadone followed by buprenorphine and then oral naltrexone, although it was noted that the available daily dose of buprenorphine (5 mg) was not an agonist dose equivalent to the study’s daily dose of methadone (50 mg)—which likely contributed to poorer retention in the buprenorphine-treated group.⁵²

Impact on HIV Risk Behaviors

In HIV-infected populations, methadone and buprenorphine maintenance significantly reduce the use of illicit opioids and the risk of HIV transmission through the use of injection drugs, though their impact is less robust on sexual risk behaviors.^{53–56} In a secondary analysis using a large national cohort from a safety RCT (comparing hepatic responses to 24 weeks methadone and buprenorphine maintenance for OUD),⁵⁷ an interesting gender difference emerged: sexual risk behaviors increased among men maintained on buprenorphine but decreased in methadone-maintained men, whereas women decreased risk with either buprenorphine or methadone maintenance.⁵¹

Impact on Hepatitis C Risk Behaviors

Cumulative, lifetime HCV seroprevalence estimates among injection-drug users is up to 90%,⁵⁸ with high seroconversion rates attributable to both sharing syringes/needles and sharing drug preparation equipment (e.g., drug cookers and spoons, filtration cottons, vehicle fluids).^{59,60} Two large, prospective cohort studies report the protective effect of methadone^{61,62} and buprenorphine⁶² maintenance, but not detoxification, in preventing HCV seroconversion among adult injection-drug users who are HCV negative at treatment entry.

Impact on Preventing Opioid Overdose

Several risk factors for unintended opioid overdose have been identified. They include misuse of heroin and opioid analgesics, misuse of diverted buprenorphine and methadone, increases in opioid prescribing, having four or more prescribers or pharmacies filling opioid prescriptions, being prescribed doses equivalent to more than 100 mg morphine, opioid ingestion coupled with alcohol or the use of other sedatives/

hypnotics (with synergistic effects on respiratory depression), receipt of public subsidy income providing access to drug purchase and binge drug use, suboptimal methadone-induction practices in relation to both pain management and addiction, opioid-analgesic switching, previous overdose history, loss of opioid tolerance among OUD due either to extended abstinence during incarceration or to treatment-related abstinence, and older age, with smoking status and co-occurring medical conditions likely contributing to fatalities.^{2,63–71} Given that MAT reduces illicit opioid use, educates about OUD and accidental-overdose prevention, and may provide (where available) intranasal naloxone rescue kits to family and friends for use at the scene of an opioid overdose,^{68,72} it is expected that MAT would be an important factor in preventing accidental opioid-overdose deaths occurring in those with OUD while they remain in active treatment. While data to date suggest that that is indeed the case for buprenorphine, methadone, and naltrexone ER,^{19,63} more data are required to judge the safety of MAT following treatment dropout and planned medication discontinuation, particularly for antagonist therapies for which the preclinical²⁰ and clinical^{28,31,73} evidence indicates increased risk for respiratory depression upon opioid agonist reexposure.

Safety Profile of MAT

Buprenorphine and methadone⁵⁷ and naltrexone ER^{19,74} maintenance have favorable safety profiles, with HCV-infection being the most common predictor of mild-to-moderate increases in transaminases among adults, pregnant women,⁷⁵ and youth.^{26,76} Methadone risk for QTc prolongation (associated with torsades de pointes, which has an estimated 10%–17% risk of sudden death due to cardiac arrhythmia⁷⁷) is dose dependent, but screening baseline QTc intervals has not yet been shown to assist risk management during methadone maintenance.⁷⁸ Neither buprenorphine nor naltrexone is associated with QTc prolongation.

Drug-drug interactions are numerous with methadone, due to many cytochrome P450 isoenzymes involved in its hepatic metabolism (mainly CYP3A4, but also CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6).^{12,18} Metabolic inhibitors that increase methadone peak concentrations pose a risk for sedation and respiratory depression, bowel immotility, and QTc prolongation and cardiac arrhythmia; whereas metabolic potentiators that reduce methadone peak and trough concentrations pose a risk for opioid withdrawal and relapse to opioid use. Other substances and drugs having similar adverse effects (sedation, reduced bowel motility, QTc prolongation, and reductions in heart rate, blood pressure, and respiratory rate) may pose additive and synergistic effects, even if they do not alter methadone metabolism. Common examples include alcohol and benzodiazepines (sedation and reduced respiratory drive), antipsychotics, tricyclic antidepressants, and calcium channel blockers (QTc prolongation), and psychotropics with anticholinergic effects (constipation).

By comparison, buprenorphine and naltrexone have few drug-drug interactions and a benign side-effect profile. Owing to its partial-agonist properties, buprenorphine is not associated with a significant risk for respiratory depression;⁴⁷ however, in combination with sedatives/hypnotics (especially diazepam),^{79–81} it poses a risk for sedation and reduced respiratory drive. Naltrexone has no risk for reduced respiratory drive, but attempts to “override” blockade with high-dose opioid use poses a risk for accidental-overdose death (see Vivitrol® package insert). Buprenorphine is metabolized primarily by CYP3A4 and has clinically significant drug-drug interactions with rifampin (reductions in buprenorphine concentrations pose a risk for opioid withdrawal, although this effect is not observed with rifabutin)⁸² and atazanavir (increased buprenorphine concentration and sedation/cognitive impairment).⁸³ Buprenorphine has not had confirmed, clinically significant CYP3A4 or CYP2D6 interactions with other commonly prescribed psychotropics and medications, although infrequent case reports exist; definitive human studies are lacking.^{18,84} Naltrexone is not metabolized by cytochrome P450 isoenzymes; instead, it has hepatic metabolism via dihydrodiol dehydrogenase to β -naltrexol, which is then conjugated for urinary excretion.⁸⁴ Its major drug interaction is blockade of opioid analgesic efficacy.

In pregnancy, naltrexone ER has no demonstrated safety, whereas both buprenorphine and methadone maintenance are safe and effective for maintaining maternal abstinence and retention in prenatal care,⁸⁵ and are safely recommended during breastfeeding.^{86,87} Buprenorphine demonstrates less peak-dosing suppression of fetal heart rate, fetal heart rate reactivity, and biophysical profile scores, and generates a milder neonatal abstinence syndrome than methadone.^{88,89} Early neonatal development appears within normal limits for infants exposed to buprenorphine or methadone in utero.⁹⁰ Longer-term neurodevelopmental safety is known for infants exposed in utero to methadone⁹¹ and is being investigated for buprenorphine-exposed infants.

Ease of Induction and Comparison of Available MAT Formulary

The MAT formulary available in the United States for treating OUD is summarized in Table 3. Naltrexone ER is available only under a brand name, whereas buprenorphine monotherapy, buprenorphine/naloxone, and methadone are all available both generically and under brand names. Oral methadone concentrates are dose-equivalent, but the differences in formulations for buprenorphine/naloxone are not reliably dose-equivalent (see, e.g., the dosing differences with buccal film). Converting between these forms of buprenorphine/naloxone requires careful attention to dosing practices (food and smoking should be avoided 30 minutes before and after dosing, and dissolved medication should be held with saliva for a full 10 minutes to optimize mucosal absorption) and to patient response. General dosing ranges for both induction

Table 3			
Opioid Use Disorder Formulary in the United States			
Available formulary	Dosage forms (mg)	Induction dosing (mg)	Recommended dosing range for stabilization/maintenance (mg)
Methadone (HCl oral concentrate, per ml)			
Generic	5, 10	5–10 every 4 hours up to 40 in the first 24 hours	Gradual titration with close monitoring over 2 weeks to 60–120 daily; rapid metabolizers may require higher dosing
Methadose	10		
Methadose sugar-free	10		
Methadone HCl Intensol	10		
Buprenorphine + naloxone			
Sublingual tablet			
Generic	2/0.5, 8/2	2/0.5–4/1; repeat up to 16/4 in the first 24 hours	4/1–24/6 daily
Zubsolv	1.4/0.36, 5.7/1.4	1.4/0.36–2.8/0.72; repeat up to 11.4/2.8 in the first 24 hours	2.8/0.72–17.1/4.2 daily
Sublingual film			
Suboxone Film	2/0.5, 4/1, 8/2, 12/3	2/0.5–4/1; repeat up to 16/4 in the first 24 hours	4/1–24/6 daily
Buccal film			
Bunavail	2.1/0.3, 4.2/0.7, 6.3/1	2.1/0.3; repeat up to 8.4/1.4 in the first 24 hours	2.1/0.3–12.6/2.1 daily
Buprenorphine			
Sublingual tablet (generic only)	2, 8	2–4; up to 16 in the first 24 hours	4–24 daily
Naltrexone ER			
Vivitrol	380	380 IM following agonist clearance; oral naltrexone 50 mg daily may precede or supplement initial induction	380 IM every 4 weeks; oral naltrexone may be added to supplement in weeks 3–4 as needed
ER, extended release.			

and for stabilization/maintenance treatment are also listed in Table 3.

An advantage of methadone is that it can be started at any time during an overarching course of treatment. A disadvantage, however, is that it takes time to achieve a steady-state dose that is therapeutically effective in OUD, and this time period is one of high risk for treatment dropout and accidental overdose if titration is too rapid.^{17,92} Buprenorphine requires the individual to be in mild-moderate opioid withdrawal prior to dosing, in order to avoid precipitating severe opioid withdrawal (due to its partial-agonist activity), but relief is achieved within 24–72 hours of induction for both monotherapy and the naloxone-combined product. The partial-agonist “ceiling effect” protects against respiratory depression, thus rendering this medication safe for rapid induction. Buprenorphine monotherapy is recommended for observed induction and for stabilizing or maintaining pregnant women or those that

may respond adversely to naloxone due to allergies or co-occurring medical conditions. The combination product is buprenorphine plus naloxone in a 4:1 ratio and was designed to prevent misuse and diversion of buprenorphine among injection drug users. Buprenorphine has good bioavailability via oral mucosal absorption, whereas naloxone does not. Taken sublingually, the naloxone component has poor bioavailability, but if crushed and injected, the naloxone component is readily available to exert opioid antagonist effects, thus reducing the risk of abuse in buprenorphine treatment. Buprenorphine/naloxone is consequently the formula of choice for inductions that are not fully observed and for routine maintenance, in order to reduce product diversion and misuse. Naltrexone ER has the most complicated induction profile because of the need to complete metabolism of opioid agonists prior to dosing (typically 7–14 days), thereby avoiding severe opioid withdrawal (due to its antagonist activity).

Prolonged symptoms of opioid withdrawal during washout pose a high risk for treatment dropout and relapse. Attempts to abbreviate this period require more complex dosing algorithms as well as back-up options for environmental containment to prevent relapse to opioid use.⁹³

Risk for Diversion and Negative Public Health Impact

Buprenorphine (all formulations) and methadone are known to be diverted by patients and to be commonly used illicitly,^{63,94,95} resulting in further opioid misuse and overdoses, in accidental pediatric exposures,⁹⁶ and in accidental or intentional adolescent exposures.⁶ Since naltrexone ER has no known diversion value, it allows for the treatment of OUD without contributing to illicit opioid use.

DISCUSSION

Factors to Consider in Selecting Treatment with MAT

MAT is recommended for adults presenting for clinical treatment of OUD with physiological dependence: it significantly augments treatment retention, reduces illicit opioid use, reduces the burden of opioid craving, and, in the case of agonist therapies, provides effective relief of the opioid withdrawal syndrome. Thus, MAT is a stabilizing addition to relapse-prevention counseling and mutual help groups (such as Narcotics Anonymous) in that it increases the effectiveness of those interventions. Longer-term, abstinence-based residential treatment without MAT shows limited effectiveness, especially among recently detoxified heroin users,^{97,98} and loss of tolerance during this period of abstinence poses an increased risk of fatal overdose if one relapses to opioid use upon discharge to home. Youth is a predictor of early dropout from psychosocial treatment of OUD,⁹⁹ whereas medication adherence and early opioid abstinence predict greater retention and treatment success among youth treated with buprenorphine/naloxone.¹⁰⁰ A 2005 Cochrane review noted that the available evidence was insufficient to support psychosocial treatment alone as effective for OUD.¹⁰¹ The evidence remains insufficient, even to predict which individuals, if any, are likely to do well without MAT.

The selection of MAT can be viewed from two different perspectives: individualized treatment versus population management. An individualized treatment approach will consider many factors, in addition to the evidence base, to guide medical decisions. These factors include the following: the availability of, and patient's access to, MAT; the experience of the prescribing clinician; the clinical setting of treatment; patient and family preferences; occupational risks (see next paragraph); co-occurring medical and psychiatric illnesses; and the patient's motivation for opioid abstinence, capacity to adhere to recommended treatment, and legal status. If the risk for treatment dropout is high, the evidence regarding MAT and retention in treatment significantly favors a recommendation for agonist therapy; methadone maintenance demonstrates the highest patient retention rates in all studies

comparing methadone to buprenorphine. A recommendation of methadone or buprenorphine/naloxone maintenance must also be balanced by a discussion with the patient (including informed consent) regarding both the difficulty of terminating agonist therapies (due to reexperiencing opioid withdrawal and craving) and the high rates of opioid relapse following the discontinuation of either buprenorphine^{25,26} or methadone.^{102,103} Unfortunately, no long-term studies have compared taper outcomes with buprenorphine versus methadone. Clinicians are encouraged to monitor taper trials closely for any evidence of patient destabilization or relapse risk that would require returning to higher-dose agonist treatment. The benefits of extended methadone or buprenorphine/naloxone maintenance delivered within an opioid treatment program (requiring daily medication monitoring during early recovery, and providing structured psychosocial interventions and integrated care options) are especially pronounced for populations with significant drug-related legal charges and drug-using social networks, for patients with co-occurring medical illness related to injection drug use, and for socially disadvantaged patients, who may receive, through the integrated structure of the program, the intensive social and medical services needed to support sustained recovery.

In some situations, the selection of MAT may reflect risk-benefit assessments unrelated to the medical factors as such. For instance, the performance of pilots, physicians, professional athletes, or those carrying firearms could be compromised and even be dangerous because of opioid agonist treatment's cognitive or sedative effects or its impact on reaction times.^{104,105} No studies specific to these professions have been conducted for agonist therapy of OUD, however, so this concern is empirical rather than evidence based at this time. In such cases, antagonist therapy may be preferred for a motivated, treatment-seeking individual who desires to continue such employment, despite the comparatively weak evidence supporting antagonist versus agonist therapies. Similarly, an individual with co-occurring OUD and alcohol use disorder might benefit most from antagonist therapy, given that the FDA has approved naltrexone ER as effective in preventing relapse to alcohol use.^{106,107} In all such situations, these matters should be covered in a collaborative informed consent process, and clinicians should carefully document the discussion.

A population-management approach would consider the public health impact of OUD, along with the cost-effectiveness of the available treatment options, over patient preferences and individualized selection of MAT. Primary consideration would be given to preventing opioid diversion into the community, opioid overdose deaths, and the transmission of infectious diseases (in particular, hepatitis C and HIV) through the use of injection opioids. To optimize such decisions, all three MAT options for OUD would need to be available, and prescribers would need to be trained in the appropriate use of each one. Lack of prescriber familiarity and comfort with MAT, as well as limits imposed on prescribers by managed care (e.g., dosing limits, prior authorization reviews,

and limits on toxicology), continue to be barriers to dissemination of MAT for OUD in clinical practice.¹⁰⁸ The availability of a regularly updated, evidence-based algorithm to assist in decision making would also contribute to the adoption of MAT in practice.¹⁰⁹

An example of a simple, evidence-based algorithm for MAT selection—one designed to be flexible in relation to regional MAT availability—is outlined in Text Box 2. Failed treatment trials would result in the selection of an alternate MAT treatment or in the relocation of treatment itself—for example, from an office to a structured treatment setting with closer patient monitoring, such as an opioid treatment program, an integrated mental health care clinic, or a specialized integrated care clinic (following an integrated care model as is used for infectious diseases). In the United States, methadone maintenance must currently be delivered within a federally regulated opioid treatment program, but some evidence suggests, as a future option, that methadone maintenance can be effectively delivered within an office-based setting, especially for clinically stable patients who have achieved take-home doses.^{110–112} The use and implementation of a MAT algorithm would reduce discrepancies in treatment based on regional variations, prescriber expertise, or access to specialty clinics. The main weakness of this approach, however, is that it could reduce the role of patient preferences in selecting MAT. This consideration is a serious one in framing an effective population-management

approach since patient engagement in substance use treatment is essential for optimal outcomes. Service-utilization research and feedback from programs using this approach are much needed.

MAT Selection in Adolescents

The buprenorphine/naloxone combination is FDA approved for adolescents aged 16 and older and has demonstrated safety and efficacy for youth with OUD.²⁶ As such, it is currently the treatment of choice. Nevertheless, concern about adolescent nonadherence and the misuse and diversion of buprenorphine/naloxone has generated some support for empirical treatment with naltrexone ER. Caution is advised, however, because evidence is lacking as to the safety and efficacy of naltrexone ER in this population. In the United States, methadone maintenance is not available for the treatment of adolescents.

MAT Selection in Women of Childbearing Age

For women of childbearing age and those who are pregnant or planning pregnancy, careful discussion, along with informed consent, is required in selecting MAT. Although methadone maintenance is the current gold standard of clinical care during pregnancy, buprenorphine monotherapy (but not buprenorphine/naloxone, though early evidence suggests that the combination warrants further study)¹¹³ is a potential alternative based on studies comparing the safety and efficacy of these treatments during pregnancy.⁸⁵ Postpartum breastfeeding mothers may

Text Box 2

Evidence-Based Medication-Assisted Treatment Selection Algorithm for Treating Opioid Use Disorder in Adults^a

A. Threshold questions

(1) Is the patient actively seeking abstinence from all illicit opioid use?

YES: consider antagonist or agonist medication-assisted treatment (MAT)

NO: consider agonist MAT to reduce risk of accidental opioid overdose death by maintaining opioid tolerance

(2) Does the patient have significant co-occurring chronic pain?

YES: consider agonist MAT to reduce pain-related opioid relapse

NO: consider antagonist or agonist MAT

B. Exclusions to extended-release antagonist maintenance

- pregnant or planning pregnancy
- foreseeable need for opioid analgesia during treatment
- recent opioid overdose or high risk for opioid overdose behavior

C. MAT treatment setting

(1) office-based outpatient care

- patients committed to abstaining from all substance use
- no recent history of accidental or intentional substance overdose
- no recent history of opioid diversion

(2) structured care setting (e.g., opioid treatment program, integrated mental health care clinic)

- recently stabilized sedative/hypnotic or alcohol use disorders
- recent history of accidental or intentional substance overdose
- patient is receiving agonist MAT and has recent history of opioid diversion

^a This algorithm is flexible in that it includes local care options and is designed to reduce opioid overdose deaths and opioid diversion. Failure of one MAT trial would prompt reconsideration of other available MAT options or the relocation of treatment from an office-based practice setting to a structured clinical setting with closer patient monitoring.

be switched from buprenorphine monotherapy to combination buprenorphine/naloxone maintenance in order to prevent diversion, especially since naloxone is poorly absorbed sublingually and is unlikely to be absorbed by suckling infants.¹¹⁴

Lack of Clinical Studies for Using MAT in Nondependent OUD

No research has examined MAT in nondependent OUD, and even case reports are lacking on this topic. Such off-label use, which would require appropriate informed consent and risk-management consultation, should not be considered without careful deliberation and documentation of medical decision making. Theoretically, OUD without any history of physiological dependence would favor antagonist treatment in most cases, as maintenance on agonist therapy will induce physiological opioid dependence. In most cases, this risk would not be perceived to outweigh benefit except in the presence of an imminent risk of death by opioid overdose. Such situations include recurrent or recent near-fatal overdoses with opioids or a recent intentional opioid overdose in an impulsive individual returning to an outpatient setting. In these examples, the preserved or augmented opioid tolerance provided by agonist treatment might be considered protective against future toxic opioid use, in which case buprenorphine/naloxone would be favored over methadone because of its lower risk of opioid toxicity and fewer drug-drug interactions. Another example may be the patient with a co-occurring pain syndrome who requires intermittent opioid analgesia, satisfies criteria for OUD without physiological dependence, but misuses opioid analgesics. In this example, low-dose buprenorphine/naloxone maintenance in a divided-dosing regimen could potentially enable pain treatment and circumvent opioid misuse; indeed, studies of OUD with physiological dependence show buprenorphine/naloxone to provide a benefit in mild-to-moderate pain syndromes.^{25,115} Note, however, that the above comments reflect theoretical considerations only; evidence for efficacy and safety is lacking for all three medications in relation to non-dependent OUD.

Need for Development of Non-opioid Therapies to Ameliorate Acute and Protracted Opioid Withdrawal Syndromes

Opioid withdrawal is commonly misrepresented as a “flu-like” syndrome due to the constellation of physical symptoms characterizing acute hyperadrenergic rebound, along with malaise and gastrointestinal distress. This concept of opioid withdrawal is incomplete, however, in that it ignores the severe affective and cognitive distress (including treatment-resistant anxiety, dysphoria/depression, severe opioid craving, and loss of self-efficacy) that persists up to 30 days in untreated OUD abstinence^{116,117} and that contributes to opioid relapse and treatment dropout, even among young OUD patients with relatively brief histories of dependence.¹¹⁸

Potential non-opioid treatments to stabilize opioid withdrawal and opioid craving may be developed through an

understanding of how neurobiological circuitry interacts with opioid pathways.¹¹⁹ Such treatments would be expected to relieve symptoms, improve retention in care, ease induction, and possibly increase the options for managing OUD during pregnancy. A small pilot RCT (n = 24) of buprenorphine detoxification with and without gabapentin, a GABAergic anti-convulsant, demonstrated better short-term opioid-use outcomes with gabapentin,¹²⁰ but two RCTs assessing the use of memantine, a glutamatergic antagonist, as an adjunct to naltrexone ER induction and stabilization¹²¹ or to oral naltrexone¹²² had negative results. Further research on novel pharmacotherapies to ease opioid withdrawal are warranted.^{123,124}

Clinicians are encouraged to educate patients about opioid withdrawal and its presenting a risk for opioid relapse and for dropping out of treatment. A collaborative plan should be developed, in advance, for managing opioid withdrawal. For example, informed consent with agonist therapies should include a discussion both of opioid withdrawal as presenting a risk for relapse and of the future inevitability of experiencing opioid withdrawal when discontinuing agonist treatment or if doses are missed. Collaborative treatment plans that include aggressive pharmacological management of symptom relief and options for safe containment in higher levels of care (such as partial or residential treatment programs) would be expected to improve retention in care and, more generally, the patient’s understanding of how to avoid relapse to opioid use.

Declaration of interest: The author reports no conflicts of interest. The author alone is responsible for the content and writing of this article.

REFERENCES

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: APA, 2013.
2. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. *MMWR Morb Mortal Wkly Rep* 2011;60:1487–92.
3. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: summary of national findings. Rockville, MD: SAMHSA, 2013. <http://www.samhsa.gov/data/sites/default/files/NSDUHnationalfindingresults2012/NSDUHnationalfindingresults2012/NSDUHresults2012.pdf>
4. Executive Office of the President of the United States. Epidemic: responding to America’s prescription drug abuse crisis. 2011. <http://publications.iowa.gov/12965/1/NationalRxAbusePlan2011.pdf>
5. Bailey JE, Campagna E, Dart RC; RADARS System Poison Center Investigators. The underrecognized toll of prescription opioid abuse on young children. *Ann Emerg Med* 2009; 53:419–24.
6. Zosel A, Bartelson BB, Bailey E, Lowenstein S, Dart R. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS®) System. *J Am Acad Child Adolesc Psychiatry* 2013;52:196–204.
7. Valdiserri R, Khalsa J, Dan C, et al. Confronting the emerging epidemic of HCV infection among young injection drug users. *Am J Public Health* 2014;104:816–21.

8. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. *N Engl J Med* 2014;370:2063–6.
9. Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. *Clin Psychol Rev* 2010;30:155–66.
10. Hill KP, Rice LS, Connery HS, Weiss RD. Diagnosing and treating opioid dependence. *J Fam Pract* 2012;61:588–97.
11. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. *J Addict Dis* 2012;31:207–25.
12. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO, 2009.
13. Correia CJ, Walsh SL, Bigelow GE, Strain EC. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. *Psychopharmacology* 2006;189:297–306.
14. Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. *Life Sci* 1994;54:1215–28.
15. Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. *J Pharmacol Exp Ther* 2014;348:217–26.
16. Sarton E, Teppema L, Dahan A. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine. *Adv Exp Med Biol* 2008;605:486–91.
17. Pilgrim JL, McDonough M, Drummer OH. A review of methadone deaths between 2001 and 2005 in Victoria, Australia. *Forensic Sci Int* 2013;226:216–22.
18. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. *Am J Addict* 2010;19:4–16.
19. Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. *Addiction* 2013;108:1628–37.
20. Diaz A, Pazos A, Florez J, Ayesta FJ, Santana V, Hurler MA. Regulation of mu-opioid receptors, G-protein-coupled receptor kinases and beta-arrestin 2 in the rat brain after chronic opioid receptor antagonism. *Neuroscience* 2002;112:345–53.
21. Volpe DA, McMahon Tobin GA, et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. *Regul Toxicol Pharmacol* 2011;59:385–90.
22. Yuan Y, Zaidi SA, Elbegdorj O, et al. Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity. *J Med Chem* 2013;56:9156–69.
23. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. *Lancet* 2011;377:1506–13.
24. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. *N Engl J Med* 2003;349:949–58.
25. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. *Arch Gen Psychiatry* 2011;68:1238–46.
26. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. *JAMA* 2008;300:2003–11.
27. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev* 2009;(3): CD002209.
28. Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. *Drug Alcohol Rev* 2007;26:405–10.
29. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? *Am J Drug Alcohol Abuse* 2006;32:503–17.
30. Kelty E, Hulse G. Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use. *Addiction* 2012;107:1817–24.
31. Degenhardt L, Larney S, Kimber J, Farrell M, Hall W. Excess mortality among opioid-using patients treated with oral naltrexone in Australia. *Drug Alcohol Rev* 2014 Oct 10 [Epub ahead of print].
32. Dunn K, DeFulio A, Everly JJ, et al. Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes. *Psychol Addict Behav* 2014 Aug 18 [Epub ahead of print].
33. Larney S, Gowing L, Mattick RP, Farrell M, Hall W, Degenhardt L. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. *Drug Alcohol Rev* 2014;33:115–28.
34. Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. *JAMA* 2010;304:1576–83.
35. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev* 2014;2:CD002207.
36. DeFulio A, Everly JJ, Leoutsakos JM, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. *Drug Alcohol Depend* 2012;120:48–54.
37. Everly JJ, DeFulio A, Koffarnus MN, et al. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. *Addiction* 2011;106:1309–18.
38. Thompson G, Kelly E, Christopoulos A, Canals M. Novel GPCR paradigms at the mu-opioid receptor. *Br J Pharmacol* 2015;172:287–96.
39. Williams JT, Ingram SL, Henderson G, et al. Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. *Pharmacol Rev* 2013;65:223–54.
40. Birdsong WT, Arttamangkul S, Clark MJ, et al. Increased agonist affinity at the mu-opioid receptor induced by prolonged agonist exposure. *J Neurosci* 2013;33:4118–27.
41. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. *Pain Physician* 2012;15 (3 suppl):ES67–92.
42. Haerian BS, Haerian MS. OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. *Pharmacogenomics* 2013;14:813–24.
43. Whistler JL. Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology. *Drug Alcohol Depend* 2012;121:189–204.
44. Grecksch G, Bartzsch K, Widera A, Becker A, Hollt V, Koch T. Development of tolerance and sensitization to different opioid agonists in rats. *Psychopharmacology* 2006;186:177–84.
45. Hajj A, Khabbaz L, Laplanche JL, Peoc'h K. Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. *Pharmacogenomics* 2013;14:575–85.

46. Dennis BB, Bawor M, Thabane L, Sohani Z, Samaan Z. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. *PLoS One* 2014;9:e86114.
47. Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. *Palliat Med* 2006;20 suppl 1:s3–8.
48. Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence. A current perspective. *West J Med* 1990;152:588–99.
49. Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. *Addiction* 2014;109:79–87.
50. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. *Cochrane Database Syst Rev* 2013;12:CD006318.
51. Woody G, Bruce D, Korthuis PT, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. *J Acquir Immune Defic Syndr* 2014;66:288–93.
52. Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. *Eur J Clin Invest* 2003;33:824–9.
53. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. *Cochrane Database Syst Rev* 2011;(8):CD004145.
54. Edelman EJ, Chantarat T, Caffrey S, et al. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. *Drug Alcohol Depend* 2014;139:79–85.
55. Otiaashvili D, Piralishvili G, Sikhharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—outcomes of a randomized trial. *Drug Alcohol Depend* 2013;133:376–82.
56. Meade CS, Weiss RD, Fitzmaurice GM, et al. HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. *J Acquir Immune Defic Syndr* 2010;55:65–72.
57. Saxon AJ, Ling W, Hillhouse M, et al. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. *Drug Alcohol Depend* 2013;128:71–6.
58. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. *Am J Epidemiol* 2008;168:1099–109.
59. Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. *Addiction* 2012;107:1057–65.
60. Palmateer N, Hutchinson S, McAllister G, et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. *J Viral Hepat* 2014;21:25–32.
61. Nolan S, Dias Lima V, Fairbairn N, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. *Addiction* 2014;109:2053–9.
62. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. *JAMA Intern Med* 2014;174:1974–81.
63. Wikner BN, Ohman I, Selden T, Druid H, Brandt L, Kieler H. Opioid-related mortality and filled prescriptions for buprenorphine and methadone. *Drug Alcohol Rev* 2014;33:491–8.
64. Baublatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. *JAMA Intern Med* 2014;174:796–801.
65. Chou R, Weimer MB, Dana T. Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. *J Pain* 2014;15:338–65.
66. Zlotorzynska M, Milloy MJ, Richardson L, et al. Timing of income assistance payment and overdose patterns at a Canadian supervised injection facility. *Int J Drug Policy* 2014;25:736–9.
67. Darke S. Opioid overdose and the power of old myths: what we thought we knew, what we do know and why it matters. *Drug Alcohol Rev* 2014;33:109–14.
68. Walley AY, Doe-Simkins M, Quinn E, Pierce C, Xuan Z, Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. *J Subst Abuse Treat* 2013;44:241–7.
69. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. *Addiction* 1999;94:961–72.
70. Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. *Pain Med* 2014;15:1911–29.
71. Madadi P, Hildebrandt D, Lauwers AE, Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. *PLoS One* 2013;8:e60600.
72. Centers for Disease Control and Prevention. Community-based opioid overdose prevention programs providing naloxone—United States, 2010. *MMWR Morb Mortal Wkly Rep* 2012;61:101–5.
73. Ritter AJ. Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose. *Aust N Z J Psychiatry* 2002;36:224–8.
74. Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. *J Stud Alcohol Drugs* 2012;73:991–7.
75. McNicholas LF, Holbrook AM, O’Grady KE, et al. Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. *Addiction* 2012;117:91–7.
76. Bogenschutz MP, Abbott PJ, Kushner R, Tonigan JS, Woody GE. Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults. *J Addict Med* 2010;4:211–6.
77. Fung MC, Hsiao-hui Wu H, Kwong K, Hornbuckle K, Muniz E. Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades—1969–1998. *Pharmacoepidemiol Drug Saf* 2000;9:S24.
78. Pani PP, Trogu E, Maremmanni I, Pacini M. QTc interval screening for cardiac risk in methadone treatment of opioid dependence. *Cochrane Database Syst Rev* 2013;6:CD008939.
79. Lintzeris N, Mitchell TB, Bond AJ, Nestor L, Strang J. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. *Drug Alcohol Depend* 2007;91:187–94.
80. Cohier C, Chevillard L, Risede P, Roussel O, Megarbane B. Respiratory effects of buprenorphine/naloxone alone and in

- combination with diazepam in naive and tolerant rats. *Toxicol Lett* 2014;228:75–84.
81. Lintzeris N, Mitchell TB, Bond A, Nestor L, Strang J. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. *J Clin Psychopharmacol* 2006;26:274–83.
 82. McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. *Drug Alcohol Depend* 2011;118:326–34.
 83. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. *Drug Alcohol Depend* 2007;91:269–78.
 84. Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. *Am J Drug Alcohol Abuse* 2011;37:1–11.
 85. Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. *Addiction* 2012;115:5–27.
 86. Gower S, Bartu A, Ilett KF, Doherty D, McLaurin R, Hamilton D. The wellbeing of infants exposed to buprenorphine via breast milk at 4 weeks of age. *J Hum Lact* 2014;30:217–23.
 87. Pritham UA. Breastfeeding promotion for management of neonatal abstinence syndrome. *J Obstet Gynecol Neonatal Nurs* 2013;42:517–26.
 88. Gaalema DE, Scott TL, Heil SH, et al. Differences in the profile of neonatal abstinence syndrome signs in methadone-versus buprenorphine-exposed neonates. *Addiction* 2012;113:53–62.
 89. Salisbury AL, Coyle MG, O’Grady KE, et al. Fetal assessment before and after dosing with buprenorphine or methadone. *Addiction* 2012;113:36–44.
 90. Coyle MG, Salisbury AL, Lester BM, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. *Addiction* 2012;113:63–73.
 91. Kaltenbach K, Finnegan LP. Developmental outcome of children born to methadone maintained women: a review of longitudinal studies. *Neurobehav Toxicol Teratol* 1984;6:271–5.
 92. Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. *Addiction* 2009;104:1193–200.
 93. Sigmon SC, Bisaga A, Nunes EV, O’Connor PG, Kosten T, Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. *Am J Drug Alcohol Abuse* 2012;38:187–99.
 94. Larance B, Lintzeris N, Ali R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. *Drug Alcohol Depend* 2014;136:21–7.
 95. Schuman-Olivier Z, Connery H, Griffin ML, et al. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. *Am J Addict* 2013;22:574–80.
 96. Pedapati EV, Bateman ST. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone. *Pediatr Crit Care Med* 2011;12:e102–7.
 97. Keen J, Oliver P, Rowse G, Mathers N. Residential rehabilitation for drug users: a review of 13 months’ intake to a therapeutic community. *Fam Pract* 2001;18:545–8.
 98. Kosten TR, Gorelick DA. The Lexington narcotic farm. *Am J Psychiatry* 2002;159:22.
 99. McHugh RK, Murray HW, Hearon BA, et al. Predictors of dropout from psychosocial treatment in opioid-dependent outpatients. *Am J Addict* 2013;22:18–22.
 100. Warden D, Subramaniam GA, Carmody T, et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. *Addict Behav* 2012;37:1046–53.
 101. Mayet S, Farrell M, Ferri M, Amato L, Davoli M. Psychosocial treatment for opiate abuse and dependence. *Cochrane Database Syst Rev* 2005;(1):CD004330.
 102. Masson CL, Barnett PG, Sees KL, et al. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. *Addiction* 2004;99:718–26.
 103. Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. *Mt Sinai J Med* 2001;68:62–74.
 104. Soyka M. Opioids and traffic safety—focus on buprenorphine. *Pharmacopsychiatry* 2014;47:7–17.
 105. Rapeli P, Fabritius C, Kalska H, Alho H. Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates. *BMC Clin Pharmacol* 2011;11:13.
 106. Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. *JAMA* 2005;293:1617–25.
 107. O’Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. *J Clin Psychopharmacol* 2007;27:507–12.
 108. Heinrich CJ, Cummings GR. Adoption and diffusion of evidence-based addiction medications in substance abuse treatment. *Health Serv Res* 2014;49:127–52.
 109. Lang K, Neil J, Wright J, Dell CA, Berenbaum S, El-Aneed A. Qualitative investigation of barriers to accessing care by people who inject drugs in Saskatoon, Canada: perspectives of service providers. *Subst Abuse Treat Prev Policy* 2013;8:8–35.
 110. Fiellin DA, O’Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. *JAMA* 2001;286:1724–31.
 111. Roux P, Michel L, Cohen J, et al. Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial. *BMC Public Health* 2012;12:488.
 112. Kahan M, Wilson L, Midmer D, Ordean A, Lim H. Short-term outcomes in patients attending a primary care-based addiction shared care program. *Can Fam Physician* 2009;55:1108–9.
 113. Debelak K, Morrone WR, O’Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy—initial patient care and outcome data. *Am J Addict* 2013;22:252–4.
 114. ToxNet. LactMed. 2014. <http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm>
 115. Neumann AM, Blondell RD, Jaanimagi U, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. *J Addict Dis* 2013;32:68–78.
 116. Shi J, Li SX, Zhang XL, et al. Time-dependent neuroendocrine alterations and drug craving during the first month of abstinence in heroin addicts. *Am J Drug Alcohol Abuse* 2009;35:267–72.
 117. Li SX, Shi J, Epstein DH, et al. Circadian alteration in neurobiology during 30 days of abstinence in heroin users. *Biol Psychiatry* 2009;65:905–12.
 118. Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents:

- a randomized controlled trial. *Arch Gen Psychiatry* 2005;62:1157–64.
119. Chartoff EH, Connery HS. It's MORE exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. *Front Pharmacol* 2014;5:116.
120. Sanders NC, Mancino MJ, Gentry WB, et al. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. *Exp Clin Psychopharmacol* 2013;21:294–302.
121. Bisaga A, Sullivan MA, Glass A, et al. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. *J Subst Abuse Treat* 2014;46:546–52.
122. Bisaga A, Sullivan MA, Cheng WY, et al. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. *Drug Alcohol Depend* 2011;119:e23–9.
123. Tabatabai SM, Dashti S, Doosti F, Hosseinzadeh H. Phytotherapy of opioid dependence and withdrawal syndrome: a review. *Phytother Res* 2014;28:811–30.
124. Gao JL, Tu SA, Liu J, et al. An-jun-ning, a traditional herbal formula, attenuates spontaneous withdrawal symptoms via modulation of the dopamine system in morphine-dependent rats. *BMC Complement Altern Med* 2014;14:308.